TITLE

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C

AUTHOR(S)
Siebert, U.; Sroczynski, G.; Rossol, S.; Wasem, J.; Ravens-Sieberer, U.; Kurth, B.M.; Manns, M.P.; McHutchison, J.G.; Wong, J.B.
PUB. DATE
March 2003
SOURCE
Gut;Mar2003, Vol. 52 Issue 3, p425
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Peginterferon α-2b plus ribavirin therapy in previously untreated patients with chronic hepatitis C yields the highest sustained virological response rates of any treatment strategy but is expensive. Aims: To estimate the cost effectiveness of treatment with peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of patients with chronic hepatitis C. Methods: Individual patient level data from a randomised clinical trial with peginterferon plus ribavirin were applied to a previously published and validated Markov model to project lifelong clinical outcomes. Quality of life and economic estimates were based on German patient data. We used a societal perspective and applied a 3% annual discount rate. Results: Compared with no antiviral therapy, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 4.2 and 4.7 years, respectively. Compared with standard interferon α-2b plus ribavirin, peginterferon plus fixed or weight based dosing of ribavirin increased life expectancy by 0.5 and by 1.0 years with incremental cost effectiveness ratios of €11 800 and €6600 per quality adjusted life year (QALY), respectively. Subgroup analyses by genotype, viral load, sex, and histology showed that peginterferon plus weight based ribavirin remained cost effective compared with other well accepted medical treatments. Conclusions: Peginterferon α-2b plus ribavirin should reduce the incidence of liver complications, prolong life, improve quality of life, and be cost effective for the initial treatment of chronic hepatitis C.
ACCESSION #
9747202

 

Related Articles

  • Review: Interferon-α plus ribavirin improves the virologic response in chronic hepatitis C. Reichen, Juerg // ACP Journal Club;Jul/Aug2002, Vol. 137 Issue 1, p17 

    Provides information on a study that examined whether interferon-α plus ribavirin more effective than interferon-α alone for improving hepatitis C virologic response and liver-related morbidity and mortality in patients with chronic hepatitis C. Data sources; Study selection; Main...

  • FDA Drug Approvals: Rebetol.  // Formulary;Sep2003, Vol. 38 Issue 9, p514 

    Reports on the approval of the ribavirin drug Rebetol from Schering-Plough, the first combination therapy for treatment of hepatitis C in children. Efficacy of the drug in trials; Requirement for dose modification; Dosage.

  • HLA class I B44 is associated with sustained response to interferon + ribavirin therapy in patients with chronic hepatitis C. Romero-Gómez, Manuel; González-Escribano, María Francisca; Torres, Belén; Barroso, Natalia; Montes-Cano, Marco Antonio; Sánchez-Muñoz, Diego; Núñez-Roldan, Antonio; Aguilar-Reina, José // American Journal of Gastroenterology;Jul2003, Vol. 98 Issue 7, p1621 

    : ObjectiveThe aim of this study was to assess the influence of host genetic factors on response to combination therapy for chronic hepatitis C infection.: MethodsPatients with biopsy-proved chronic hepatitis C infection were treated with interferon alone (n = 143) or combined therapy of...

  • Immunological markers predicting outcome in patients with hepatitis C treated with interferon-α and ribavirin. Lee, Silvia; Macquillan, Gerry C; Keane, Niamh M; Flexman, James; Jeffrey, Gary P; French, Martyn Ah; Brochier, Jean; Price, Patricia // Immunology & Cell Biology;Aug2002, Vol. 80 Issue 4, p391 

    Summary Type 1 (T1) cytokine responses are required for the clearance of hepatitis C virus by cytotoxic T lymphocytes, but can promote liver damage. Interferon-α (IFNα) can be expected to promote T1 cytokine responses, so treatment outcome may depend on the T1/T2 cytokine environment and...

  • Peginterferon-α-2a/ribavirin.  // Reactions Weekly;10/1/2011, Issue 1371, p30 

    The article describes the case of a 53-year-old man who developed bronchial cast expectoration while being treated with peginterferon-&alpha-2a and ribavirin for chronic hepatitis C.

  • A Randomized, Controlled Trial to Determine Whether Continued Ribavirin Monotherapy in Hepatitis C Virus--Infected Patients Who Responded to Interferon-Ribavirin Combination Therapy Will Enhance Sustained Virologic Response.  // Journal of Infectious Diseases;8/15/2001, Vol. 184 Issue 4, p405 

    This study assessed the use of ribavirin monotherapy to enhance sustained virologic response in hepatitis C virus (HCV)-infected patients who achieved virologic response to interferon (IFN)-ribavirin combination therapy. Patients who had chronic HCV infection and prior relapse were retreated...

  • Peginterferon-α-2b/ribavirin.  // Reactions Weekly;10/20/2012, Issue 1424, p40 

    The article describes the case of a 62-year-old man who developed branch retinal artery occlusion (BRAO) and central retinal vein occlusion (CRVO) during treatment with peginterferon-α-2b and ribavirin for chronic hepatitis C infection.

  • Filgrastim/peginterferon-α-2a/ribavirin.  // Reactions Weekly;1/29/2011, Issue 1336, p22 

    The article describes the case report of a 54-year-old female patient with chronic hepatitis C, and who developed severe recurrent neutropenia, thrombocytopenia and agranulocytosis during long-term therapy with SC peginterferon-α-2a combined with ribavirin.

  • Peginterferon/ribavirin.  // Reactions Weekly;11/13/2010, Issue 1327, p30 

    The article describes the case of depression and fatigue in two men while receiving treatment with peginterferon and ribavirin for chronic hepatitis C.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics